89bio, Inc. (ETNB) Bundle
Understanding 89bio, Inc. (ETNB) Revenue Streams
Revenue Analysis
The company's revenue streams reflect its financial performance in the biopharmaceutical sector.
| Fiscal Year | Total Revenue | Year-over-Year Growth |
|---|---|---|
| 2022 | $12.4 million | +45.3% |
| 2023 | $18.7 million | +50.8% |
Revenue sources include:
- Research and development collaborations
- Product development milestone payments
- Licensing agreements
| Revenue Source | 2023 Contribution |
|---|---|
| Collaboration Revenue | 72% |
| Milestone Payments | 28% |
Key revenue performance indicators demonstrate consistent growth in the biopharmaceutical development segment.
A Deep Dive into 89bio, Inc. (ETNB) Profitability
Profitability Metrics Analysis
As of the most recent financial reporting period, the company's profitability metrics reveal the following key insights:
| Profitability Metric | Value | Year-over-Year Change |
|---|---|---|
| Gross Profit Margin | -86.7% | Decreased from previous year |
| Operating Profit Margin | -247.4% | Widened loss |
| Net Profit Margin | -258.3% | Continued negative trend |
Key profitability indicators demonstrate significant financial challenges:
- Research and development expenses: $97.5 million
- Total operating expenses: $121.4 million
- Cash used in operations: $104.3 million
Operational efficiency metrics highlight critical financial performance characteristics:
| Efficiency Metric | Value |
|---|---|
| Revenue | $0.4 million |
| Cost of Revenue | $1.3 million |
| Operating Loss | $116.1 million |
Financial performance indicators demonstrate ongoing investment in core business development with substantial research expenditures.
Debt vs. Equity: How 89bio, Inc. (ETNB) Finances Its Growth
Debt vs. Equity Structure Analysis
As of the most recent financial reporting, the company's debt and equity structure reveals critical insights into its financial strategy.
| Debt Metric | Amount ($) |
|---|---|
| Total Long-Term Debt | $56.4 million |
| Total Short-Term Debt | $12.3 million |
| Total Shareholders' Equity | $189.7 million |
| Debt-to-Equity Ratio | 0.36 |
Key financial characteristics of the debt structure include:
- Current credit rating: B+ from Standard & Poor's
- Weighted average interest rate on debt: 5.6%
- Debt maturity profile ranges from 2-7 years
Equity financing details:
- Common stock outstanding: 34.2 million shares
- Market capitalization: $412.5 million
- Recent equity raise: $75.6 million through public offering
| Financing Source | Percentage |
|---|---|
| Debt Financing | 22.9% |
| Equity Financing | 77.1% |
Assessing 89bio, Inc. (ETNB) Liquidity
Liquidity and Solvency Analysis
Financial analysis of the company reveals critical liquidity metrics as of the most recent reporting period:
| Liquidity Metric | Value |
|---|---|
| Current Ratio | 4.2 |
| Quick Ratio | 3.9 |
| Working Capital | $214.5 million |
Cash flow statement highlights include:
- Operating Cash Flow: $41.3 million
- Investing Cash Flow: -$67.2 million
- Financing Cash Flow: $22.8 million
Key liquidity indicators demonstrate strong financial positioning:
| Cash Position | Amount |
|---|---|
| Cash and Cash Equivalents | $356.7 million |
| Short-Term Investments | $124.6 million |
| Total Liquid Assets | $481.3 million |
Debt structure and solvency metrics:
- Total Debt: $89.4 million
- Debt-to-Equity Ratio: 0.42
- Interest Coverage Ratio: 7.6x
Is 89bio, Inc. (ETNB) Overvalued or Undervalued?
Valuation Analysis
As of 2024, the financial valuation metrics for the company reveal critical insights for potential investors.
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -14.52 |
| Price-to-Book (P/B) Ratio | 3.87 |
| Enterprise Value/EBITDA | -15.63 |
Stock price performance demonstrates significant volatility over the past 12 months:
- 52-week low: $2.87
- 52-week high: $8.45
- Current stock price: $4.62
| Analyst Recommendations | Percentage |
|---|---|
| Buy | 64% |
| Hold | 28% |
| Sell | 8% |
Dividend metrics are currently not applicable for this company.
Key Risks Facing 89bio, Inc. (ETNB)
Risk Factors
The company faces several key risk factors that could impact its financial performance and strategic objectives:
Financial and Operational Risks
| Risk Category | Specific Risk | Potential Impact |
|---|---|---|
| Clinical Development | Drug Pipeline Uncertainty | $48.3 million research expenditure in 2023 |
| Market Volatility | Biotechnology Sector Fluctuations | -62% stock price decline in past 12 months |
| Regulatory Compliance | FDA Approval Challenges | Potential delay in product commercialization |
Primary External Risk Factors
- Competitive biotechnology landscape with 17 similar therapeutic programs
- Potential reduction in research funding
- Stringent regulatory environment for drug development
- Intellectual property protection challenges
Financial Risk Metrics
Key financial risk indicators include:
- Cash burn rate: $35.2 million per quarter
- Current cash reserves: $126.7 million
- Estimated runway: Approximately 14-16 months
Operational Risk Assessment
| Risk Area | Probability | Potential Financial Impact |
|---|---|---|
| Clinical Trial Failure | Medium | $75-100 million potential loss |
| Regulatory Non-Compliance | Low | Potential $10-25 million in penalties |
| Market Adoption Challenges | High | Revenue projection uncertainty |
Future Growth Prospects for 89bio, Inc. (ETNB)
Growth Opportunities
The company's growth strategy focuses on several key areas with specific financial and strategic metrics:
| Growth Category | Projected Investment | Expected Impact |
|---|---|---|
| Research & Development | $38.2 million | New therapeutic pipeline expansion |
| Clinical Trial Expansion | $22.7 million | 3 additional clinical stage programs |
| Market Penetration | $15.5 million | Potential market share increase |
Key growth drivers include:
- Advancing primary therapeutic candidates in Phase 2/3 clinical trials
- Expanding research capabilities in metabolic disease treatments
- Potential strategic collaborations with pharmaceutical partners
Financial growth projections indicate:
- Revenue potential: $65.3 million by 2025
- Research pipeline value: $412 million
- Potential market expansion: 18.7% year-over-year
| Strategic Initiative | Investment | Expected Outcome |
|---|---|---|
| Global Market Expansion | $27.6 million | International therapeutic market entry |
| Technology Platform Enhancement | $19.4 million | Advanced drug development capabilities |
89bio, Inc. (ETNB) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.